JP2007063177A - Composition for oral intake intended for lustrous skin - Google Patents
Composition for oral intake intended for lustrous skin Download PDFInfo
- Publication number
- JP2007063177A JP2007063177A JP2005250453A JP2005250453A JP2007063177A JP 2007063177 A JP2007063177 A JP 2007063177A JP 2005250453 A JP2005250453 A JP 2005250453A JP 2005250453 A JP2005250453 A JP 2005250453A JP 2007063177 A JP2007063177 A JP 2007063177A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- composition
- ascorbic acid
- wrinkles
- hyaluronic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 56
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 78
- 235000000069 L-ascorbic acid Nutrition 0.000 claims abstract description 49
- 239000002211 L-ascorbic acid Substances 0.000 claims abstract description 40
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 40
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 38
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 38
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 38
- 230000037303 wrinkles Effects 0.000 claims abstract description 34
- 230000037406 food intake Effects 0.000 claims description 18
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 9
- 230000009471 action Effects 0.000 claims description 7
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 5
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 5
- 229960002442 glucosamine Drugs 0.000 claims description 5
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 4
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 4
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims 1
- -1 L-ascorbic acid compound Chemical class 0.000 abstract description 17
- 238000013329 compounding Methods 0.000 abstract description 4
- 210000003491 skin Anatomy 0.000 description 57
- 239000000047 product Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- 238000009472 formulation Methods 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 11
- 230000006872 improvement Effects 0.000 description 11
- 150000000996 L-ascorbic acids Chemical class 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 210000000434 stratum corneum Anatomy 0.000 description 8
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000005068 transpiration Effects 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 235000017471 coenzyme Q10 Nutrition 0.000 description 3
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 3
- 229940110767 coenzyme Q10 Drugs 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 239000000845 maltitol Substances 0.000 description 3
- 235000010449 maltitol Nutrition 0.000 description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 3
- 229940035436 maltitol Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 238000004299 exfoliation Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940025878 hesperidin Drugs 0.000 description 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- DBSABEYSGXPBTA-RXSVEWSESA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical class OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DBSABEYSGXPBTA-RXSVEWSESA-N 0.000 description 1
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 description 1
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- PFPQMWRASYNLMZ-LGIMBNBCSA-N 2-(3,4-dihydroxyphenyl)-3-[(2s,3r,4r,5s,6r)-3,4-dihydroxy-5-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-5,7-dihydroxychromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 PFPQMWRASYNLMZ-LGIMBNBCSA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- HDTRYLNUVZCQOY-BTLHAWITSA-N alpha,beta-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-BTLHAWITSA-N 0.000 description 1
- FYGDTMLNYKFZSV-DZOUCCHMSA-N alpha-D-Glcp-(1->4)-alpha-D-Glcp-(1->4)-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-DZOUCCHMSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- HDTRYLNUVZCQOY-NCFXGAEVSA-N beta,beta-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-NCFXGAEVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002214 flavonoid derivatives Chemical class 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000008123 high-intensity sweetener Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明は、肌の弛み、シワ及び／又はコジワを改善する美肌用の経口摂取用組成物に関する。 The present invention relates to a composition for oral intake for beautifying skin that improves skin sag, wrinkles and / or wrinkles.
従来から、肌の弛み、シワ及びコジワを改善し、美しい肌を保つことは多くの人々が希望とするところであり、これらを目的とする種々の製品が開発されている。これらの製品は、一般には化粧品という形態で提供され皮膚に塗布されるものが多いが、他方においては経口的に摂取されることにより上記目的を達成しようとする製品もある。 Conventionally, many people have desired to improve skin slackness, wrinkles and wrinkles, and to keep beautiful skin, and various products for these purposes have been developed. Many of these products are generally provided in the form of cosmetics and applied to the skin. On the other hand, there are products that try to achieve the above-mentioned purpose by being taken orally.
ヒアルロン酸は、真皮層に多く存在し、皮膚の保湿性や弾力性に関与していることが知られている。そのため、皮膚の保湿性や弾力性の維持を目的にした、ヒアルロン酸を含有させた食品が幾つか開発されている（特許文献１、特許文献２参照）。 Hyaluronic acid is abundant in the dermis layer and is known to be involved in the moisture retention and elasticity of the skin. For this reason, several foods containing hyaluronic acid have been developed for the purpose of maintaining the moisture retention and elasticity of the skin (see Patent Document 1 and Patent Document 2).
Ｌ−アスコルビン酸類は、皮膚や粘膜の健康維持を助ける抗酸化ビタミンとして、或いは、抗酸化剤として経口摂取用の組成物に利用されている（特許文献３）。また、Ｌ−アスコルビン酸類は、メラニンの生成を抑制することから、美白用の化粧料にも使用されている（特許文献４）。また、Ｌ−アスコルビン酸類を利用した、コラーゲン産生増強用の組成物も提案されている（特許文献５）。しながら、特定の割合で、ヒアルロン酸とＬ−アスコルビン酸類とを経口的に摂取することにより、肌の弛み、シワ及び／又はコジワを改善する美肌効果が顕著に発揮されることについての報告はない。 L-ascorbic acids are used in compositions for oral intake as antioxidant vitamins that help maintain the health of skin and mucous membranes or as antioxidants (Patent Document 3). L-ascorbic acids are also used in whitening cosmetics because they suppress the production of melanin (Patent Document 4). A composition for enhancing collagen production using L-ascorbic acids has also been proposed (Patent Document 5). However, there is a report that the skin beautifying effect that improves skin slackness, wrinkles and / or wrinkles is remarkably exhibited by taking hyaluronic acid and L-ascorbic acid orally at a specific ratio Absent.
本発明は、肌の弛み、シワ及び／又はコジワを改善し、肌荒れの改善や肌のうるおいの向上を達成することができる経口摂取用の組成物を提供することを課題とする。 An object of the present invention is to provide a composition for oral intake that can improve skin looseness, wrinkles and / or wrinkles, and can achieve improvement of rough skin and improvement of moisture of the skin.
本発明者は、上記課題を解決するために、鋭意研究した結果、特定の割合でヒアルロン酸およびＬ−アスコルビン酸類を併せて経口的に摂取すると、効果的に美しい肌を保つことができることを見出し、本発明を完成した。すなわち、本発明は、ヒアルロン酸とＬ−アスコルビン酸に換算したときのＬ−アスコルビン酸類との配合割合が、質量比で１：４乃至４：１である経口摂取用組成物を提供することにより上記課題を解決するものである。 As a result of earnest research to solve the above problems, the present inventor has found that when hyaluronic acid and L-ascorbic acids are taken orally in a specific ratio, beautiful skin can be effectively maintained. The present invention has been completed. That is, the present invention provides a composition for oral consumption in which the blending ratio of hyaluronic acid and L-ascorbic acid when converted to L-ascorbic acid is 1: 4 to 4: 1 by mass ratio. The present invention solves the above problems.
本発明の経口摂取用組成物は経口摂取することにより、摂取した者の、肌の弛み、シワ及び／又はコジワを改善すると共に、角層のバリア機能を改善し、皮膚の保水力を高め、肌荒れの改善、肌のうるおいが向上し、美しい肌が保持される。 The composition for oral ingestion of the present invention, when orally ingested, improves the slackness, wrinkles and / or wrinkles of the ingested person, improves the barrier function of the stratum corneum, and enhances the water retention capacity of the skin, Improves rough skin, improves moisture and keeps beautiful skin.
本発明の経口摂取用組成物に使用するヒアルロン酸は、化学合成されたものでもよく、発酵法で製造したものや、動物の組織や微生物等から抽出したものであっても良い。ヒアルロン酸は、本発明の効果を妨げない限り、必ずしも精製または単離されたものを用いる必要はなく、未分離組成物としての形態、それらを部分精製、或いは、高度に精製したものであってもよい。また、本発明の経口摂取用組成物に含まれるヒアルロン酸は、その少なくとも一部がヒアルロン酸ナトリウムなどの塩の形態になっていてもよい。 The hyaluronic acid used in the composition for oral ingestion of the present invention may be chemically synthesized, may be produced by fermentation, or may be extracted from animal tissues or microorganisms. Hyaluronic acid does not necessarily need to be purified or isolated as long as it does not interfere with the effects of the present invention, and is in the form of an unseparated composition, partially purified or highly purified. Also good. Moreover, at least a part of the hyaluronic acid contained in the composition for oral consumption of the present invention may be in the form of a salt such as sodium hyaluronate.
本発明の経口摂取用組成物に含まれるヒアルロン酸の含有量は、特に制限はなく、通常は、該組成物全質量に対して０．１質量％乃至２５質量％であることが好ましい。 There is no restriction | limiting in particular in content of the hyaluronic acid contained in the composition for oral intake of this invention, Usually, it is preferable that it is 0.1 mass% thru | or 25 mass% with respect to this composition total mass.
本発明で使用するＬ−アスコルビン酸類としては、経口摂取が可能で、生体内において、ビタミンＣとしての生理機能を発揮できるものであれば、特に限定されない。具体的には、例えば、Ｌ−アスコルビン酸や、Ｌ−アスコルビン酸配糖体、Ｌ−アスコルビン酸脂肪酸エステル、Ｌ−アスコルビン酸リン酸エステルなどのＬ−アスコルビン酸の誘導体、ニコチン酸アミド−Ｌアスコルビン酸複合体、これらＬ−アスコルビン酸類のアルカリ金属塩又はアルカリ土類金属塩の他、アンモニウム塩、アミノ酸塩等の塩も同様に使用することができる。なかでも、Ｌ−アスコルビン酸配糖体の１種であるＬ−アスコルビン酸２−グルコシドは、経口摂取用組成物に配合しても安定であるばかりでなく、経口摂取すると、生体内で徐々に分解されて、持続的にビタミンＣ作用を発揮し、ヒアルロン酸と組み合わせた場合には、他のＬ−アスコルビン酸類に比して、強い美肌作用を持続することができるので、特に望ましい。 The L-ascorbic acid used in the present invention is not particularly limited as long as it can be taken orally and can exhibit physiological functions as vitamin C in vivo. Specifically, for example, L-ascorbic acid, L-ascorbic acid glycosides, L-ascorbic acid fatty acid esters, L-ascorbic acid phosphates and other derivatives of L-ascorbic acid, nicotinamide-L ascorbine In addition to acid complexes and alkali metal salts or alkaline earth metal salts of these L-ascorbic acids, salts such as ammonium salts and amino acid salts can also be used. Among them, L-ascorbic acid 2-glucoside, which is one of L-ascorbic acid glycosides, is not only stable even when blended in an oral intake composition, but gradually in vivo when ingested. When it is decomposed and continuously exerts vitamin C action and is combined with hyaluronic acid, it is particularly desirable because it can maintain a strong skin beautifying action compared to other L-ascorbic acids.
本発明の経口摂取用組成物に含まれるＬ−アスコルビン酸類の含有量は、特に制限はなく、通常は、Ｌ−アスコルビン酸に換算して、該組成物全質量に対して０．１質量％乃至２５質量％であることが好ましい。 The content of L-ascorbic acid contained in the composition for oral consumption of the present invention is not particularly limited, and is usually 0.1% by mass in terms of the total mass of the composition in terms of L-ascorbic acid. It is preferable that it is thru | or 25 mass%.
本発明の経口摂取用組成物におけるヒアルロン酸とＬ−アスコルビン酸類との配合割合は、本発明の所期の作用効果が達成できればよく、ヒアルロン酸とＬ−アスコルビン酸に換算したときのＬ−アスコルビン酸類との配合割合が、質量比で１：４乃至４：１、望ましくは１：２乃至２：１のものが、美肌効果の点で優れている。 The blending ratio of hyaluronic acid and L-ascorbic acid in the composition for oral consumption of the present invention is only required to achieve the intended effect of the present invention. L-ascorbine when converted to hyaluronic acid and L-ascorbic acid A compounding ratio with acids is 1: 4 to 4: 1, preferably 1: 2 to 2: 1 in terms of mass ratio, which is excellent in terms of skin beautifying effect.
また、このヒアルロン酸とＬ−アスコルビン酸類との経口摂取は、これらの２成分を含む組成物を摂取することが望ましいが、ヒアルロン酸とＬ−アスコルビン酸に換算したときのＬ−アスコルビン酸類との摂取割合が、質量比で１：４乃至４：１となるように、各々の成分を、別々に経口摂取する場合も、本発明に含まれる。 Moreover, although it is desirable to ingest these hyaluronic acid and L-ascorbic acids with a composition containing these two components, the hyaluronic acid and the L-ascorbic acids when converted to L-ascorbic acid are preferable. The case where each component is orally ingested separately so that the ingestion ratio is 1: 4 to 4: 1 by mass ratio is also included in the present invention.
本発明の経口摂取物組成物の成人１日当たりの摂取量は、所期の作用効果が達成できる限り、特に制限はないが、通常は、ヒアルロン酸の摂取量及びＬ−アスコルビン酸に換算したときのＬ−アスコルビン酸類の摂取量は、何れも、１日当たり６０ｍｇ以上とするのが望ましく、９０ｍｇ以上が好適であり、１２０ｍｇ以上とするのが特に望ましい。 The daily intake of the oral ingestion composition of the present invention is not particularly limited as long as the desired effect can be achieved, but usually when converted into hyaluronic acid intake and L-ascorbic acid In any case, the intake of L-ascorbic acid is preferably 60 mg or more, more preferably 90 mg or more, and particularly preferably 120 mg or more.
本発明の経口摂取用組成物は、本発明の作用効果を妨げない範囲で、ヒアルロン酸及びＬ−アスコルビン酸類以外の、通常経口摂取用組成物に加えられる成分を任意に含有させることができる。例えば、ブドウ糖、果糖、グルコサミン、ラクトース、蔗糖、α，α−トレハロース、α，β−トレハロース、β，β−トレハロース、ラクトスクロース、マルトオリゴ糖、水飴などの糖類、サイクロデキストリンや同じ出願人による国際公開ＷＯ ０２／１０３６１号明細書などに記載のサイクロ｛→６）−α−Ｄ−グルコピラノシル−（１→３）−α−Ｄ−グルコピラノシル−（１→６）−α−Ｄ−グルコピラノシル−（１→３）−α−Ｄ−グルコピラノシル−（１→｝の構造を有する環状四糖、或いは、特開２００５−９５１４８号公報（特願２００４−１７４８８０号明細書）などに記載のサイクロ｛→６）−α−Ｄ−グルコピラノシル−（１→４）−α−Ｄ−グルコピラノシル−（１→６）−α−Ｄ−グルコピラノシル−（１→４）−α−Ｄ−グルコピラノシル−（１→｝の構造を有する環状四糖などの環状の糖類、エリスリトール、マンニトール、ソルビトール、キシリトール、マルチトール、還元水飴などの糖アルコール類、アスパルテーム、ステビア抽出物、スクラロース、アセスルファムＫなどの高甘味度甘味料、プルラン、カラギーナン、コンドロイチン硫酸などのムコ多糖体やその塩類、天然ガム類、キチン、キトサン、カルボキシメチルセルロースをはじめとする合成高分子ポリマー、コラーゲン、ゼラチンなどの増粘剤の何れか１種又は２種以上を添加することができる。なかでも、コンドロイチン硫酸やグルコサミンを併用することにより、本発明の経口摂取用組成物の美肌効果を、より増強することができる。 The composition for oral ingestion of the present invention can optionally contain components that are usually added to the composition for oral ingestion other than hyaluronic acid and L-ascorbic acids, as long as the effects of the present invention are not hindered. For example, sugars such as glucose, fructose, glucosamine, lactose, sucrose, α, α-trehalose, α, β-trehalose, β, β-trehalose, lactosucrose, maltooligosaccharide, varicella, cyclodextrin and international publication by the same applicant Cyclo {→ 6) -α-D-glucopyranosyl- (1 → 3) -α-D-glucopyranosyl- (1 → 6) -α-D-glucopyranosyl- (1 →) described in WO 02/10361 3) Cyclic tetrasaccharide having a structure of -α-D-glucopyranosyl- (1 →) or cyclo {→ 6)-described in JP-A-2005-95148 (Japanese Patent Application No. 2004-174880) etc. α-D-glucopyranosyl- (1 → 4) -α-D-glucopyranosyl- (1 → 6) -α-D-glucopyranosyl- (1 → 4) -α-D Cyclic sugars such as cyclic tetrasaccharides having the structure of glucopyranosyl- (1 →}, sugar alcohols such as erythritol, mannitol, sorbitol, xylitol, maltitol, reduced starch syrup, aspartame, stevia extract, sucralose, acesulfame K, etc. High-intensity sweeteners, mucopolysaccharides such as pullulan, carrageenan, chondroitin sulfate and their salts, natural gums, chitin, chitosan, synthetic polymer polymers such as carboxymethylcellulose, thickeners such as collagen and gelatin In particular, the skin beautifying effect of the composition for oral consumption of the present invention can be further enhanced by using chondroitin sulfate or glucosamine in combination.
また、本発明の経口摂取用組成物には、上記以外にも、例えば、ビタミンＢ１、ビタミンＢ２、ビタミンＢ６、ビタミンＢ１２、ビタミンＥ、ルチン・ヘスペリジン・ナリンジンなどのバイオフラボノイド類或いは、これらビタミンやフラボノイドの誘導体など、アミノ酸類、ＣｏＱ１０（コエンザイムＱ１０）、アデノシンやその誘導体、それらのモノフォスフェイト、ジフォスフェイト或いはトリフォスフェイトのような核酸関連物質、プロポリス、フラボノイド類などの成分、海洋深層水などのミネラル類、賦形剤、結合剤、被覆剤、滑沢剤、崩壊剤、増量剤、抗酸化剤、矯味矯臭剤、呈味剤、乳化・可溶化・分散剤、安定剤、ｐＨ調節剤、着色料、香料、甘味料、酸味料などから選ばれる何れか１種又は２種以上を含有させることも随意である。 In addition to the above, the composition for oral consumption of the present invention includes, for example, bioflavonoids such as vitamin B 1 , vitamin B 2 , vitamin B 6 , vitamin B 12 , vitamin E, rutin, hesperidin, naringin, etc. , Amino acids such as vitamins and flavonoid derivatives, CoQ10 (coenzyme Q10), adenosine and derivatives thereof, nucleic acid related substances such as monophosphate, diphosphate or triphosphate, propolis, flavonoids, and other components , Minerals such as deep sea water, excipients, binders, coating agents, lubricants, disintegrants, extenders, antioxidants, flavoring agents, flavoring agents, emulsifying / solubilizing / dispersing agents, stability Any one or more selected from agents, pH adjusters, colorants, flavors, sweeteners, acidulants, etc. And it is also optional.
本発明の経口摂取用組成物は、ヒアルロン酸及びＬ−アスコルビン酸類を、該組成物が完成するまでの工程で、或いは、完成品に対して、含有せしめればよく、その具体的な方法としては、例えば、混和、混捏、溶解、融解、分散、懸濁、乳化、浸透、晶出、散布、塗布、付着、噴霧、被覆（コーティング）、注入、浸漬、固化、逆ミセル化などの、飲食品の製造に使用することのできる１種又は２種以上の方法の組み合わせが適宜に選ばれる。 The composition for oral ingestion of the present invention may contain hyaluronic acid and L-ascorbic acid in the process until the composition is completed or in the finished product. For example, mixing, kneading, dissolving, melting, dispersing, suspending, emulsifying, penetrating, crystallization, spraying, applying, adhering, spraying, coating (coating), pouring, dipping, solidifying, reverse micelle, etc. One or a combination of two or more methods that can be used for the production of the product is appropriately selected.
本発明の経口摂取用組成物は、その形状を問わず、例えば、液状、シラップ、マスキット、ペースト、粉末、固状、半固状、顆粒、錠剤、ゲルなどの何れの形状であってもよく、そのままで、又は、必要に応じて、増量剤、賦形剤、結合剤などと混合して、液剤、乳剤、懸濁剤、シラップ剤、ペースト、顆粒剤、粉末剤、錠剤、カプセル剤など各種剤型で使用することもできる。 The composition for oral consumption of the present invention may be in any shape, for example, liquid, syrup, muskit, paste, powder, solid, semi-solid, granule, tablet, gel, etc. , As is, or mixed with bulking agents, excipients, binders, etc. as necessary, as liquids, emulsions, suspensions, syrups, pastes, granules, powders, tablets, capsules, etc. It can also be used in various dosage forms.
以下、実験例により本発明をさらに詳細に説明する。 Hereinafter, the present invention will be described in more detail with reference to experimental examples.
＜実験例１：ヒアルロン酸及び／又はＬ−アスコルビン酸類の経口摂取の肌に及ぼす影響＞
ヒアルロン酸及び／又はＬ−アスコルビン酸類の経口摂取の肌に及ぼす影響を調べる試験を以下のように行った。すなわち、ヒアルロン酸と、Ｌ−アスコルビン酸、Ｌ−アスコルビン酸２−グルコシド（株式会社林原商事販売、商品名「アスコフレッシュ」）、Ｌ−アスコルビン酸脂肪酸エステル、滑潤剤としてショ糖脂肪酸エステル、及び、賦形剤として精製マルトース（株式会社林原商事販売、商品名「サンマルトＳ」）を、表１に示す質量比で混合して、全量を１０質量部として、これを常法により打錠して、各々０．３ｇ／錠の錠剤を調製した。その各々の配合の錠剤につき、各々１７名の被験者に、１日当たり６錠を、３ヶ月間経口摂取させた。各々の被験者について、肌の状態を、下記評価方法１乃至評価方法３を用いて評価し、その結果を表１に示す。なお、Ｌ−アスコルビン酸２−グルコシド及びＬ−アスコルビン酸脂肪酸エステルの配合量は、Ｌ−アスコルビン酸に換算した量を表１に示した。なお、陰性対照として、これらの錠剤を摂取しなかった被験者１７名についても、同様に評価を行い、その結果を併せて表１に示す。
＜評価方法１＞
摂取前、摂取２ヵ月後及び３ヵ月後に頬の角層水分蒸散量をＴＥＷＡメーター（テヴァメーター）により測定した。配合例毎に被験者１７名の頬からの角層水分蒸散量の平均値を求めた。
＜評価方法２＞
各々の被験者を、摂取前及び摂取３ヵ月後に、角層の重層剥離の程度について観察し、摂取前に比してどのような変化が認められたかを、５段階にスコア化した（１：減少した、２：少し減少した、３：変化無し、４：少し増加した、５：増加した）。各配合の錠剤を摂取した１７名の被験者ごとにスコアの平均を求めた。
＜評価方法３＞
各々の被験者から、摂取３ヵ月後に肌のかさつきの程度と、肌の弛み、シワ及びコジワの変化についてのアンケート調査を行った。それぞれの項目に関して改善を自覚した者の割合を改善率とした。
<Experimental Example 1: Effect of oral intake of hyaluronic acid and / or L-ascorbic acid on skin>
A test for examining the effect of oral intake of hyaluronic acid and / or L-ascorbic acid on the skin was performed as follows. That is, hyaluronic acid, L-ascorbic acid, L-ascorbic acid 2-glucoside (sales by Hayashibara Corporation, trade name “ASCOFRESH”), L-ascorbic acid fatty acid ester, sucrose fatty acid ester as a lubricant, and Purified maltose (trade name “Sanmalto S”, sold by Hayashibara Co., Ltd.) as an excipient was mixed at a mass ratio shown in Table 1, and the total amount was 10 parts by mass. Each tablet was prepared at 0.3 g / tablet. For each tablet of each formulation, 17 subjects each took 6 tablets per day for 3 months. For each subject, the skin condition was evaluated using the following evaluation methods 1 to 3, and the results are shown in Table 1. In addition, the compounding quantity of L-ascorbic acid 2-glucoside and L-ascorbic acid fatty acid ester showed the quantity converted into L-ascorbic acid in Table 1. As a negative control, 17 subjects who did not take these tablets were similarly evaluated, and the results are shown in Table 1.
<Evaluation method 1>
Before ingestion, 2 months after ingestion and 3 months later, the amount of transpiration of the stratum corneum in the cheek was measured with a TEWA meter (Tevameter). The average value of the horny layer moisture transpiration from the cheeks of 17 subjects was determined for each formulation example.
<Evaluation method 2>
Each subject was observed for the degree of delamination of the stratum corneum before ingestion and after 3 months of ingestion, and the change observed compared to before ingestion was scored in 5 stages (1: decrease) 2: slightly decreased, 3: no change, 4: increased slightly, 5: increased). The average score was calculated for each of 17 subjects who took tablets of each formulation.
<Evaluation method 3>
Each subject conducted a questionnaire survey on the degree of skin roughness, skin looseness, wrinkles and changes in wrinkles 3 months after ingestion. The percentage of those who were aware of improvement in each item was taken as the improvement rate.
＜結果＞
表１から明らかなよう、ヒアルロン酸或いはＬ−アスコルビン酸類を単独で摂取した場合（配合Ｎｏ．１乃至配合Ｎｏ．４）には、頬からの水分蒸散量、角層の重層剥離の程度、肌のかさつきの程度、肌の弛み、シワ及びコジワを改善の程度の何れにおいても、摂取前に比して変化は認められなかった。これに対して、ヒアルロン酸とＬ−アスコルビン酸類を等質量配合した錠剤を摂取した場合（配合Ｎｏ．５乃至配合Ｎｏ．７）には、評価に使用した何れの項目においても、摂取前に比して改善が認められた。また、ヒアルロン酸と組み合わせるＬ−アスコルビン酸類としては、Ｌ−アスコルビン酸２−グルコシドを使用した場合に最も強い改善効果が認められた。
<Result>
As is clear from Table 1, when hyaluronic acid or L-ascorbic acid was ingested alone (Formulation No. 1 to No. 4), the amount of water transpiration from the cheeks, the degree of exfoliation of the stratum corneum, and the skin No change was observed in any of the degree of bulkiness, skin looseness, wrinkles and wrinkles to improve. On the other hand, when taking tablets containing equal amounts of hyaluronic acid and L-ascorbic acid (formulation No. 5 to No. 7), any of the items used for evaluation were compared with those before ingestion. Improvement was observed. Moreover, as L-ascorbic acid combined with hyaluronic acid, the strongest improvement effect was recognized when L-ascorbic acid 2-glucoside was used.
＜実験例２：ヒアルロン酸及びＬ−アスコルビン酸類の摂取量の及ぼす肌への影響＞
ヒアルロン酸及びＬ−アスコルビン酸類の摂取量の及ぼす肌への影響を調べる実験を以下のようにして行った。即ち、実験例１で調製した配合Ｎｏ．６のヒアルロン酸とＬ−アスコルビン酸２−グルコシドとを等質量配合した錠剤を使用して、１日当たり、１錠、２錠、３錠、４錠、５錠、或いは６錠の何れかを、各々１７名の被験者に２ヶ月間摂取させた。各々の被験者について、実験終了時の、被験者の頬の皮膚の状態を、実験例１と同じ評価方法１乃至評価方法３を用いて評価し、その結果を表２に示す。なお、実験例２と実験例１とは、被験者が重複しないように実験を行った。
<Experimental Example 2: Effects on the skin of hyaluronic acid and L-ascorbic acid intake>
An experiment for examining the effect on the skin of the intake of hyaluronic acid and L-ascorbic acid was performed as follows. That is, the formulation No. prepared in Experimental Example 1 was obtained. 6 tablets of hyaluronic acid and L-ascorbic acid 2-glucoside in an equal mass are used, and one tablet, two tablets, three tablets, four tablets, five tablets, or six tablets per day, Each of 17 subjects ingested for 2 months. For each subject, the condition of the subject's cheek skin at the end of the experiment was evaluated using the same evaluation methods 1 to 3 as in Experimental Example 1, and the results are shown in Table 2. In addition, the experiment example 2 and the experiment example 1 were conducted so that the subjects did not overlap.
表２から明らかなように、錠剤を１日当たり１錠摂取した場合には、評価に使用した何れの項目においても、摂取前に比して改善は認められなかった。これに対して、１日当たり、２錠を摂取した場合には、評価に使用した何れの項目においても、摂取前に比して改善が認められ、その改善は、１日当たり３錠以上の摂取で顕著であった。 As is apparent from Table 2, when one tablet was taken per day, no improvement was observed in any of the items used for the evaluation as compared to before the intake. On the other hand, when taking 2 tablets per day, improvement was observed in all items used for evaluation compared to before taking, and the improvement was achieved by taking 3 tablets or more per day. It was remarkable.
＜実験例３：経口摂取用組成物中のヒアルロン酸とＬ−アスコルビン酸類との配合割合の肌に及ぼす影響＞
実験例１で、ヒアルロン酸とＬ−アスコルビン酸類とを組み合わせて経口摂取することにより、肌の弛み、シワ及びコジワが改善されることが確認されたので、経口摂取用組成物中のヒアルロン酸とＬ−アスコルビン酸類との配合割合の肌に及ぼす影響を調べる試験を以下のように行った。すなわち、ヒアルロン酸と、Ｌ−アスコルビン酸２−グルコシド（株式会社林原商事販売、商品名「アスコフレッシュ」）、ショ糖脂肪酸エステル、賦形剤として精製マルトース（株式会社林原商事販売、商品名「サンマルトＳ」）を表３に示す質量比で混合して、全量を１０質量部とし、これを常法により打錠して、各々０．３ｇ／錠の錠剤を調製した。その各々の配合につき、各々１７名の被験者に、１日当たり６錠、３ヶ月間経口摂取させた。各々の被験者について、実験終了時の被験者の肌の状態を、実験例１と同じ評価方法１乃至評価方法３を用いて評価し、その結果を表３に示す。なお、Ｌ−アスコルビン酸２−グルコシドの配合量は、Ｌ−アスコルビン酸に換算した量を表３に示した。なお、実験例３と、実験例１、実験例２とは、何れも被験者が重複しないように実験を行った。
<Experimental example 3: Effect of blending ratio of hyaluronic acid and L-ascorbic acid in composition for oral consumption on skin>
Since it was confirmed in Experimental Example 1 that hyaluronic acid and L-ascorbic acid were orally ingested to improve skin looseness, wrinkles and wrinkles, hyaluronic acid in the composition for oral ingestion and The test which investigates the influence which the mixing | blending ratio with L-ascorbic acid has on the skin was done as follows. That is, hyaluronic acid, L-ascorbic acid 2-glucoside (Hayashibara Shoji Co., Ltd., trade name “Asco Fresh”), sucrose fatty acid ester, and refined maltose as excipient (Hayashibara Shoji Co., Ltd., trade name “Sanmaruto” S ") was mixed at a mass ratio shown in Table 3 to make the total amount 10 parts by weight, and this was tableted by a conventional method to prepare 0.3 g / tablet tablets each. For each formulation, 17 subjects each were orally ingested 6 tablets per day for 3 months. For each subject, the skin condition of the subject at the end of the experiment was evaluated using the same evaluation method 1 to evaluation method 3 as in Experimental Example 1, and the results are shown in Table 3. In addition, the compounding quantity of L-ascorbic acid 2-glucoside showed the quantity converted into L-ascorbic acid in Table 3. Note that in Experiment Example 3, Experiment Example 1, and Experiment Example 2, the experiment was performed so that the subjects did not overlap.
表３から明らかなように、ヒアルロン酸とＬ−アスコルビン酸を、質量比で１：４乃至４：１（配合Ｎｏ．３乃至配合Ｎｏ．９）の割合で、とりわけ１：２乃至２：１の割合で配合した錠剤を摂取した場合（配合Ｎｏ．５乃至配合Ｎｏ．７）には、評価に使用した角質の水分蒸散量、角層の重層剥離の程度、肌のかさつきの程度、肌の弛み、シワ及びコジワの改善の何れの項目においても、改善が認められた。これに対して、ヒアルロン酸とＬ−アスコルビン酸を、０．１：１．９（配合Ｎｏ．１）、０．２：１．８（配合Ｎｏ．２）、１．８：０．２（配合Ｎｏ．１０）、或いは、１．９：０．１（配合Ｎｏ．１１）の配合割合としたものでは、肌の弛み、シワ及びコジワについては、何れも摂取前に比して改善は認められなかった。 As is apparent from Table 3, hyaluronic acid and L-ascorbic acid were mixed at a mass ratio of 1: 4 to 4: 1 (formulation No. 3 to formulation No. 9), particularly 1: 2 to 2: 1. Ingestion of tablets formulated at a ratio of (No. 5 to No. 7), the amount of transpiration of keratin used in the evaluation, the degree of exfoliation of the stratum corneum, the degree of skin roughness, Improvement was recognized in any of the items of improvement of sagging, wrinkles and wrinkles. On the other hand, hyaluronic acid and L-ascorbic acid were 0.1: 1.9 (formulation No. 1), 0.2: 1.8 (formulation No. 2), 1.8: 0.2 ( In the blending ratio of No. 10) or 1.9: 0.1 (blending No. 11), the skin looseness, wrinkles and wrinkles were all improved compared to before intake. I couldn't.
これらの実験結果は、ヒアルロン酸とＬ−アスコルビン酸に換算したときのＬ−アスコルビン酸類とを、質量比で１：４乃至４：１の割合で、さらに望ましくは１：２乃至２：１の割合で配合した経口摂取用組成物が、肌の弛み、シワ及びコジワを改善し、潤いのある肌とする、優れた美肌作用を有していることを物語っている。 These experimental results show that hyaluronic acid and L-ascorbic acid converted to L-ascorbic acid are in a mass ratio of 1: 4 to 4: 1, more preferably 1: 2 to 2: 1. It indicates that the composition for oral intake formulated in a proportion has excellent skin-beautifying action that improves skin slackness, wrinkles and wrinkles, and makes the skin moist.
以下、実施例により本発明をさらに詳細に説明するが、本発明はこれら実施例に何ら限定されるものではない。 EXAMPLES Hereinafter, although an Example demonstrates this invention further in detail, this invention is not limited to these Examples at all.
＜美肌用の経口摂取用組成物＞
精製マルトース（株式会社林原商事販売、
商品名「サンマルトＳ」） ６３．５質量部
含水結晶α，α−トレハロース（株式会社
林原商事販売、商品名「トレハ」） ２５質量部
滑沢剤 ５質量部
牡蠣殻カルシウム ２質量部
ヒアルロン酸 ２質量部
Ｌ−アスコルビン酸２−グルコシド（株式会社
林原商事販売、商品名「アスコフレッシユ」） １質量部
糖転移ルチン（東洋精糖株式会社販売、商品名
「αＧルチンＰ」） ０．５質量部
酸味料（有機酸類） 適 量
レモン及びライムのフレーバー 適 量
全量を１００質量部とし、これらの成分を均質になるまで攪拌混合し、常法により、０．５ｇずつ打錠して、錠剤を調製した。
<Composition for oral intake for beautiful skin>
Refined maltose (Hayashibara Corporation sales,
Product name “Sanmalto S”) 63.5 parts by weight Water-containing crystal α, α-trehalose (Hayashibara Shoji Co., Ltd., trade name “Treha”) 25 parts by weight Lubricant 5 parts by weight Oyster shell calcium 2 parts by weight Hyaluronic acid 2 1 part by mass L-ascorbic acid 2-glucoside (trade name “Asco-Freshille” sold by Hayashibara Shoji Co., Ltd.) 1 part by mass sugar transfer rutin (sold by Toyo Seika Co., Ltd., trade name “αG rutin P”) 0.5 part by mass Acidulant (organic acids) Appropriate amount Lemon and lime flavor Appropriate amount Make the total amount 100 parts by weight, stir and mix these ingredients until homogenous, and tablet by 0.5g by a conventional method to prepare tablets did.
本品は、肌の弛み、シワ及び／又はコジワを改善することができる。また、本品は、角層のバリア機能を改善し、皮膚の保水力を高め、肌荒れの改善し、肌のうるおいの向上することができる。本品はこれらの作用効果を標榜して、美肌用の健康補助食品として販売することもできる。 This product can improve skin looseness, wrinkles and / or wrinkles. In addition, this product can improve the barrier function of the stratum corneum, increase the water retention capacity of the skin, improve the rough skin, and improve the moisture of the skin. This product can also be marketed as a health supplement for beautifying skin with these action effects.
＜美肌用の経口摂取用組成物＞
粉末マルチトール ５００質量部
アスコルビン酸２−グルコシド（株式会社
林原商事販売、商品名「アスコフレッシユ」） ５０質量部
ヒアルロン酸 ２５質量部
粉末卵黄 １９０質量部
脱脂粉乳 ２００質量部
塩化ナトリウム ４．４質量部
塩化カリウム １．８５質量部
硫酸マグネシウム ４質量部
コンドロイチン硫酸 ０．１質量部
グルコサミン ０．５質量部
チアミン ０．０１質量部
ビタミンＥアセテート ０．６質量部
ニコチン酸アミド ０．０４質量部
コエンザイムＱ１０ ０．０３質量部
糖転移ヘスペリジン（東洋精糖株式会社販売、
商品名「αＧヘスペリジンＰＳ」） ０．０２質量部
上記配合組成からなる配合物を調製した。この配合物２５質量部を精製水１５０質量部に均一に分散・溶解させ、２００ｇずつ褐色ガラス瓶に封入した。
<Composition for oral intake for beautiful skin>
Powdered maltitol 500 parts by weight Ascorbic acid 2-glucoside (Hayashibara Shoji Co., Ltd., trade name “ASCO Fresh”) 50 parts by weight Hyaluronic acid 25 parts by weight Powdered egg yolk 190 parts by weight Nonfat dry milk 200 parts by weight Sodium chloride 4.4 parts by weight Part Potassium chloride 1.85 parts by weight Magnesium sulfate 4 parts by weight Chondroitin sulfate 0.1 part by weight Glucosamine 0.5 part by weight Thiamine 0.01 part by weight Vitamin E acetate 0.6 part by weight Nicotinamide 0.04 part by weight Coenzyme Q10 0.03 parts by mass glycosylated hesperidin (sold by Toyo Seika Co., Ltd.,
(Product name “αG Hesperidin PS”) 0.02 parts by mass A composition comprising the above composition was prepared. 25 parts by mass of this formulation was uniformly dispersed and dissolved in 150 parts by mass of purified water, and 200 g each was enclosed in a brown glass bottle.
本品は、肌の弛み、シワ及び／又はコジワを改善することができる。また、本品は、角層のバリア機能を改善し、皮膚の保水力を高め、肌荒れの改善し、肌のうるおいの向上することができる。本品はこれらの作用効果を標榜して、美肌用の健康補助食品として販売することもできる。なお、本品は、ヒトのみならず、家畜、ペットなどの動物のための経口摂取又は、胃や腸へゾンデ等を使用して直接投与する経管投与用の組成物としても有利に利用できる。また、本品は糖転移ヘスペリジンを含んでいるので、血中脂質や血中コレステロールなどの、血中脂質の低減のために用いられる旨を標榜することも随意である。 This product can improve skin looseness, wrinkles and / or wrinkles. In addition, this product can improve the barrier function of the stratum corneum, increase the water retention capacity of the skin, improve the rough skin, and improve the moisture of the skin. This product can also be marketed as a health supplement for beautifying skin with these action effects. In addition, this product can be advantageously used as a composition for oral ingestion not only for humans but also for animals such as domestic animals and pets, or for direct administration using a sonde or the like to the stomach or intestine. . In addition, since this product contains transglycosylated hesperidin, it is also optional to advocate that it is used to reduce blood lipids such as blood lipids and blood cholesterol.
＜美肌用の経口摂取用組成物＞
粉末マルチトール ２５質量部
含水結晶α，α−トレハロース（株式会社林原商事
販売、商品名「トレハ」） ５４質量部
滑沢剤 ３質量部
Ｌ−アスコルビン酸２−グルコシド（株式会社
林原商事販売、商品名「アスコフレッシユ」） １０質量部
グルコサミン ２．５質量部
コンドロイチン硫酸ナトリウム １．５質量部
ヒアルロン酸 ４質量部
上記配合処方に基づき、これらの成分を均質になるまで攪拌混合し、常法により、０．５ｇずつ打錠して、錠剤を調製した。
<Composition for oral intake for beautiful skin>
Powdered maltitol 25 parts by weight Hydrous crystals α, α-trehalose (Hayashibara Corporation, trade name “Treha”) 54 parts by weight Lubricant 3 parts by weight L-ascorbic acid 2-glucoside (Hayashibara Corporation sales, product) 10 parts by weight Glucosamine 2.5 parts by weight Sodium chondroitin sulfate 1.5 parts by weight Hyaluronic acid 4 parts by weight Based on the above formulation, these ingredients are stirred and mixed until homogenous, Tablets were prepared by tableting 0.5 g each.
本品は、肌の弛み、シワ及び／又はコジワを改善することができる。また、本品は、角層のバリア機能を改善し、皮膚の保水力を高め、肌荒れの改善し、肌のうるおいの向上することができる。本品はこれらの作用効果を標榜して、美肌用の健康補助食品として販売することもできる。 This product can improve skin looseness, wrinkles and / or wrinkles. In addition, this product can improve the barrier function of the stratum corneum, increase the water retention capacity of the skin, improve the rough skin, and improve the moisture of the skin. This product can also be marketed as a health supplement for beautifying skin with these action effects.
本発明の経口摂取用組成物を摂取することにより、肌の弛み、シワ及び／又はコジワを改善することができるだけでなく、肌のバリア機能を高め、肌の保水力を高めることができるので、肌を美しく保つことができる。本発明は、斯くも顕著な作用効果を奏する発明であり、斯界に多大の貢献をする、誠に意義のある発明である。 By ingesting the composition for oral consumption of the present invention, not only can it improve skin slackness, wrinkles and / or wrinkles, but also can enhance the skin barrier function and increase the water retention capacity of the skin, Can keep skin beautiful. The present invention is an invention that exhibits such remarkable effects, and is a truly significant invention that contributes greatly to the world.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005250453A JP4982718B2 (en) | 2005-08-31 | 2005-08-31 | Composition for oral intake for beautiful skin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005250453A JP4982718B2 (en) | 2005-08-31 | 2005-08-31 | Composition for oral intake for beautiful skin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007063177A true JP2007063177A (en) | 2007-03-15 |
| JP4982718B2 JP4982718B2 (en) | 2012-07-25 |
Family
ID=37925769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005250453A Expired - Fee Related JP4982718B2 (en) | 2005-08-31 | 2005-08-31 | Composition for oral intake for beautiful skin |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4982718B2 (en) |
Cited By (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009116491A1 (en) | 2008-03-21 | 2009-09-24 | 株式会社林原生物化学研究所 | Monoclonal antibody specifically recognizing human interferon alpha subtype alpha-8 and mutant protein thereof |
| EP2301944A1 (en) | 2009-09-03 | 2011-03-30 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Particulate composition containing anhydrous crystalline 2-O-alpha -D-glucosyl-L-ascorbic acid, process for producing the same, and uses thereof |
| US20110171286A1 (en) * | 2010-01-13 | 2011-07-14 | Allergan, Inc. | Hyaluronic acid compositions for dermatological use |
| WO2012033218A1 (en) | 2010-09-07 | 2012-03-15 | 株式会社林原生物化学研究所 | HYDROUS CRYSTALS OF 2-O-α-D-GLUCOSYL-L-ASCORBIC ACID, POWDER CONTAINING HYDROUS CRYSTALS OF 2-O-α-D-GLUCOSYL-L-ASCORBIC ACID, METHOD FOR PRODUCING THE HYDROUS CRYSTALS, METHOD FOR PRODUCING THE POWDER, USE OF THE HYDROUS CRYSTALS, AND USE OF THE POWDER |
| WO2012121297A1 (en) | 2011-03-07 | 2012-09-13 | 株式会社林原 | METHOD FOR PRODUCING 2-O-α-D-GLUCOSYL-L-ASCORBIC ACID ANHYDROUS CRYSTAL-CONTAINING POWDER |
| US8318695B2 (en) | 2007-07-30 | 2012-11-27 | Allergan, Inc. | Tunably crosslinked polysaccharide compositions |
| US8338375B2 (en) | 2007-05-23 | 2012-12-25 | Allergan, Inc. | Packaged product |
| US8338388B2 (en) | 2003-04-10 | 2012-12-25 | Allergan, Inc. | Cross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained |
| JPWO2011007885A1 (en) * | 2009-07-16 | 2012-12-27 | サンスター株式会社 | Contains proteoglycan |
| US8357795B2 (en) | 2008-08-04 | 2013-01-22 | Allergan, Inc. | Hyaluronic acid-based gels including lidocaine |
| US8394782B2 (en) | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
| US8394784B2 (en) | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having multi-stage bioactive agent delivery |
| US8586562B2 (en) | 2010-03-12 | 2013-11-19 | Allergan Industrie, Sas | Fluid compositions for improving skin conditions |
| US8691279B2 (en) | 2010-03-22 | 2014-04-08 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
| US8697044B2 (en) | 2007-10-09 | 2014-04-15 | Allergan, Inc. | Crossed-linked hyaluronic acid and collagen and uses thereof |
| US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| US8883139B2 (en) | 2010-08-19 | 2014-11-11 | Allergan Inc. | Compositions and soft tissue replacement methods |
| US8889123B2 (en) | 2010-08-19 | 2014-11-18 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| US8946192B2 (en) | 2010-01-13 | 2015-02-03 | Allergan, Inc. | Heat stable hyaluronic acid compositions for dermatological use |
| US9005605B2 (en) | 2010-08-19 | 2015-04-14 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| US9114188B2 (en) | 2010-01-13 | 2015-08-25 | Allergan, Industrie, S.A.S. | Stable hydrogel compositions including additives |
| US9149422B2 (en) | 2011-06-03 | 2015-10-06 | Allergan, Inc. | Dermal filler compositions including antioxidants |
| US9228027B2 (en) | 2008-09-02 | 2016-01-05 | Allergan Holdings France S.A.S. | Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
| US9265761B2 (en) | 2007-11-16 | 2016-02-23 | Allergan, Inc. | Compositions and methods for treating purpura |
| US9284359B2 (en) | 2011-01-19 | 2016-03-15 | Hirosaki University | Method for mass preparation of proteoglycan |
| JP2016069286A (en) * | 2014-09-26 | 2016-05-09 | 株式会社ファンケル | L-ascorbic acid sustained-release formulation |
| US9393263B2 (en) | 2011-06-03 | 2016-07-19 | Allergan, Inc. | Dermal filler compositions including antioxidants |
| US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
| US9795711B2 (en) | 2011-09-06 | 2017-10-24 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
| US10722444B2 (en) | 2014-09-30 | 2020-07-28 | Allergan Industrie, Sas | Stable hydrogel compositions including additives |
| US11083684B2 (en) | 2011-06-03 | 2021-08-10 | Allergan Industrie, Sas | Dermal filler compositions |
| US11260015B2 (en) | 2015-02-09 | 2022-03-01 | Allergan Industrie, Sas | Compositions and methods for improving skin appearance |
| US11844878B2 (en) | 2011-09-06 | 2023-12-19 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0967262A (en) * | 1995-08-31 | 1997-03-11 | Shiseido Co Ltd | Skin activator and skin activating food |
| JP2002223726A (en) * | 2001-01-31 | 2002-08-13 | Ribateepu Seiyaku Kk | Food for beauty |
| JP2003095961A (en) * | 2001-09-27 | 2003-04-03 | Combi Corp | Skin beautifying promoter |
| JP2004250372A (en) * | 2003-02-20 | 2004-09-09 | Fancl Corp | Skin aging inhibitor/improver and/or rough skin inhibitor/improver kit |
| JP2006265287A (en) * | 2005-03-22 | 2006-10-05 | Q P Corp | Low molecular weight hyaluronic acid and/or its salt, its manufacturing process and cosmetic and food composition containing it |
| JP2007043960A (en) * | 2005-08-10 | 2007-02-22 | Towa Kagaku Kk | Energy-promoting/aging-preventing jellied food and method for producing the same |
-
2005
- 2005-08-31 JP JP2005250453A patent/JP4982718B2/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0967262A (en) * | 1995-08-31 | 1997-03-11 | Shiseido Co Ltd | Skin activator and skin activating food |
| JP2002223726A (en) * | 2001-01-31 | 2002-08-13 | Ribateepu Seiyaku Kk | Food for beauty |
| JP2003095961A (en) * | 2001-09-27 | 2003-04-03 | Combi Corp | Skin beautifying promoter |
| JP2004250372A (en) * | 2003-02-20 | 2004-09-09 | Fancl Corp | Skin aging inhibitor/improver and/or rough skin inhibitor/improver kit |
| JP2006265287A (en) * | 2005-03-22 | 2006-10-05 | Q P Corp | Low molecular weight hyaluronic acid and/or its salt, its manufacturing process and cosmetic and food composition containing it |
| JP2007043960A (en) * | 2005-08-10 | 2007-02-22 | Towa Kagaku Kk | Energy-promoting/aging-preventing jellied food and method for producing the same |
Cited By (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11045490B2 (en) | 2003-04-10 | 2021-06-29 | Allergan Industrie, Sas | Injectable monophase hydrogels |
| US10653716B2 (en) | 2003-04-10 | 2020-05-19 | Allergan Industrie, Sas | Injectable monophase hydrogels |
| US10080767B2 (en) | 2003-04-10 | 2018-09-25 | Allergan Industrie Sas | Injectable monophase hydrogels |
| US8563532B2 (en) | 2003-04-10 | 2013-10-22 | Allergan Industrie Sas | Cross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained |
| US8338388B2 (en) | 2003-04-10 | 2012-12-25 | Allergan, Inc. | Cross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained |
| US9062130B2 (en) | 2003-04-10 | 2015-06-23 | Allergan Industrie Sas | Cross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained |
| US8338375B2 (en) | 2007-05-23 | 2012-12-25 | Allergan, Inc. | Packaged product |
| US8318695B2 (en) | 2007-07-30 | 2012-11-27 | Allergan, Inc. | Tunably crosslinked polysaccharide compositions |
| US8703118B2 (en) | 2007-10-09 | 2014-04-22 | Allergan, Inc. | Crossed-linked hyaluronic acid and collagen and uses thereof |
| US8697044B2 (en) | 2007-10-09 | 2014-04-15 | Allergan, Inc. | Crossed-linked hyaluronic acid and collagen and uses thereof |
| US9265761B2 (en) | 2007-11-16 | 2016-02-23 | Allergan, Inc. | Compositions and methods for treating purpura |
| US8394782B2 (en) | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
| US8394784B2 (en) | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having multi-stage bioactive agent delivery |
| US8394783B2 (en) | 2007-11-30 | 2013-03-12 | Allergan, Inc. | Polysaccharide gel formulation having multi-stage bioactive agent delivery |
| US8853184B2 (en) | 2007-11-30 | 2014-10-07 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
| US8513216B2 (en) | 2007-11-30 | 2013-08-20 | Allergan, Inc. | Polysaccharide gel formulation having increased longevity |
| US8357782B2 (en) | 2008-03-21 | 2013-01-22 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Monoclonal antibodies specific for human interferon-alpha subtype alpha 8 |
| WO2009116491A1 (en) | 2008-03-21 | 2009-09-24 | 株式会社林原生物化学研究所 | Monoclonal antibody specifically recognizing human interferon alpha subtype alpha-8 and mutant protein thereof |
| US9238013B2 (en) | 2008-08-04 | 2016-01-19 | Allergan Industrie, Sas | Hyaluronic acid-based gels including lidocaine |
| US9089517B2 (en) | 2008-08-04 | 2015-07-28 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
| US11173232B2 (en) | 2008-08-04 | 2021-11-16 | Allergan Industrie, Sas | Hyaluronic acid-based gels including lidocaine |
| US9358322B2 (en) | 2008-08-04 | 2016-06-07 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
| US9089519B2 (en) | 2008-08-04 | 2015-07-28 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
| US8450475B2 (en) | 2008-08-04 | 2013-05-28 | Allergan, Inc. | Hyaluronic acid-based gels including lidocaine |
| US9089518B2 (en) | 2008-08-04 | 2015-07-28 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
| US10328180B2 (en) | 2008-08-04 | 2019-06-25 | Allergan Industrie, S.A.S. | Hyaluronic acid-based gels including lidocaine |
| US8822676B2 (en) | 2008-08-04 | 2014-09-02 | Allergan Industrie, Sas | Hyaluronic acid-based gels including lidocaine |
| US8357795B2 (en) | 2008-08-04 | 2013-01-22 | Allergan, Inc. | Hyaluronic acid-based gels including lidocaine |
| US11020512B2 (en) | 2008-08-04 | 2021-06-01 | Allergan Industrie, Sas | Hyaluronic acid-based gels including lidocaine |
| US10391202B2 (en) | 2008-08-04 | 2019-08-27 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
| US10485896B2 (en) | 2008-08-04 | 2019-11-26 | Allergan Industrie Sas | Hyaluronic acid-based gels including lidocaine |
| US9861570B2 (en) | 2008-09-02 | 2018-01-09 | Allergan Holdings France S.A.S. | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
| US11154484B2 (en) | 2008-09-02 | 2021-10-26 | Allergan Holdings France S.A.S. | Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
| US9228027B2 (en) | 2008-09-02 | 2016-01-05 | Allergan Holdings France S.A.S. | Threads of Hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof |
| JP5933264B2 (en) * | 2009-07-16 | 2016-06-08 | サンスター株式会社 | Contains proteoglycan |
| JPWO2011007885A1 (en) * | 2009-07-16 | 2012-12-27 | サンスター株式会社 | Contains proteoglycan |
| US9585828B2 (en) | 2009-07-16 | 2017-03-07 | Sunstar Inc. | Proteoglycan-containing material |
| US9265781B2 (en) | 2009-09-03 | 2016-02-23 | Hayashibara Co., Ltd. | Process for producing a particulate composition comprising anhydrous crystalline 2-O-alpha-D-glucosyl-L-ascorbic acid |
| US10603333B2 (en) | 2009-09-03 | 2020-03-31 | Hayashibara Co., Ltd. | Process for producing a particulate composition comprising an hydrous crystalline 2-o-alpha-d-glucosyl-ascorbic acid |
| EP2301944A1 (en) | 2009-09-03 | 2011-03-30 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Particulate composition containing anhydrous crystalline 2-O-alpha -D-glucosyl-L-ascorbic acid, process for producing the same, and uses thereof |
| EP3081573A1 (en) | 2009-09-03 | 2016-10-19 | Hayashibara Co., Ltd. | Particulate composition containing anhydrous crystalline 2-o-alpha -d-glucosyl-l-ascorbic acid, process for producing the same, and uses thereof |
| US9186368B2 (en) | 2009-09-03 | 2015-11-17 | Hayashibara Co., Ltd. | Process for producing a particulate composition comprising an hydrous crystalline 2-O-α-D-glucosyl-L-ascorbic acid |
| EP2743276A1 (en) | 2009-09-03 | 2014-06-18 | Hayashibara Co., Ltd. | Particulate composition containing anhydrous crystalline 2-O-alpha -D-glucosyl-L-ascorbic acid, process for producing the same, and uses thereof |
| US9872872B2 (en) | 2009-09-03 | 2018-01-23 | Hayashibara Co., Ltd. | Process for producing a particulate composition comprising an hydrous crystalline 2-O-α-D-glucosyl-L-ascorbic acid |
| US8765416B2 (en) | 2009-09-03 | 2014-07-01 | Hayashibara Co., Ltd. | Particulate composition containing anhydrous crystalline 2-O-alpha-D-glucosyl-L-ascorbic acid, process for producing the same, and uses thereof |
| US10449268B2 (en) | 2010-01-13 | 2019-10-22 | Allergan Industrie, S.A.S. | Stable hydrogel compositions including additives |
| US9655991B2 (en) | 2010-01-13 | 2017-05-23 | Allergan Industrie, S.A.S. | Stable hydrogel compositions including additives |
| US8946192B2 (en) | 2010-01-13 | 2015-02-03 | Allergan, Inc. | Heat stable hyaluronic acid compositions for dermatological use |
| US9333160B2 (en) | 2010-01-13 | 2016-05-10 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
| US20120225842A1 (en) * | 2010-01-13 | 2012-09-06 | Allergan, Inc. | Hyaluronic acid compositions for dermatological use |
| US9114188B2 (en) | 2010-01-13 | 2015-08-25 | Allergan, Industrie, S.A.S. | Stable hydrogel compositions including additives |
| US9855367B2 (en) | 2010-01-13 | 2018-01-02 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
| US20110171286A1 (en) * | 2010-01-13 | 2011-07-14 | Allergan, Inc. | Hyaluronic acid compositions for dermatological use |
| US10806821B2 (en) | 2010-01-13 | 2020-10-20 | Allergan Industrie, Sas | Heat stable hyaluronic acid compositions for dermatological use |
| US9585821B2 (en) | 2010-03-12 | 2017-03-07 | Allergan Industrie Sas | Methods for making compositions for improving skin conditions |
| US9125840B2 (en) | 2010-03-12 | 2015-09-08 | Allergan Industrie Sas | Methods for improving skin conditions |
| US8586562B2 (en) | 2010-03-12 | 2013-11-19 | Allergan Industrie, Sas | Fluid compositions for improving skin conditions |
| US8921338B2 (en) | 2010-03-12 | 2014-12-30 | Allergan Industrie, Sas | Fluid compositions for improving skin conditions |
| US10111984B2 (en) | 2010-03-22 | 2018-10-30 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
| US9480775B2 (en) | 2010-03-22 | 2016-11-01 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
| US10905797B2 (en) | 2010-03-22 | 2021-02-02 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
| US9012517B2 (en) | 2010-03-22 | 2015-04-21 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
| US8691279B2 (en) | 2010-03-22 | 2014-04-08 | Allergan, Inc. | Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation |
| US8883139B2 (en) | 2010-08-19 | 2014-11-11 | Allergan Inc. | Compositions and soft tissue replacement methods |
| US8889123B2 (en) | 2010-08-19 | 2014-11-18 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| US9005605B2 (en) | 2010-08-19 | 2015-04-14 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| WO2012033218A1 (en) | 2010-09-07 | 2012-03-15 | 株式会社林原生物化学研究所 | HYDROUS CRYSTALS OF 2-O-α-D-GLUCOSYL-L-ASCORBIC ACID, POWDER CONTAINING HYDROUS CRYSTALS OF 2-O-α-D-GLUCOSYL-L-ASCORBIC ACID, METHOD FOR PRODUCING THE HYDROUS CRYSTALS, METHOD FOR PRODUCING THE POWDER, USE OF THE HYDROUS CRYSTALS, AND USE OF THE POWDER |
| US9284359B2 (en) | 2011-01-19 | 2016-03-15 | Hirosaki University | Method for mass preparation of proteoglycan |
| KR20140039177A (en) | 2011-03-07 | 2014-04-01 | 가부시기가이샤하야시바라 | Method for producing 2-o-a-d-glucosyl-l-ascorbic acid anhydrous crystal-containing powder |
| WO2012121297A1 (en) | 2011-03-07 | 2012-09-13 | 株式会社林原 | METHOD FOR PRODUCING 2-O-α-D-GLUCOSYL-L-ASCORBIC ACID ANHYDROUS CRYSTAL-CONTAINING POWDER |
| US9149422B2 (en) | 2011-06-03 | 2015-10-06 | Allergan, Inc. | Dermal filler compositions including antioxidants |
| US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
| US9950092B2 (en) | 2011-06-03 | 2018-04-24 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
| US10624988B2 (en) | 2011-06-03 | 2020-04-21 | Allergan Industrie, Sas | Dermal filler compositions including antioxidants |
| US9962464B2 (en) | 2011-06-03 | 2018-05-08 | Allergan, Inc. | Dermal filler compositions including antioxidants |
| US11083684B2 (en) | 2011-06-03 | 2021-08-10 | Allergan Industrie, Sas | Dermal filler compositions |
| US9737633B2 (en) | 2011-06-03 | 2017-08-22 | Allergan, Inc. | Dermal filler compositions including antioxidants |
| US9393263B2 (en) | 2011-06-03 | 2016-07-19 | Allergan, Inc. | Dermal filler compositions including antioxidants |
| US10994049B2 (en) | 2011-06-03 | 2021-05-04 | Allergan Industrie, Sas | Dermal filler compositions for fine line treatment |
| US9795711B2 (en) | 2011-09-06 | 2017-10-24 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
| US10434214B2 (en) | 2011-09-06 | 2019-10-08 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
| US11844878B2 (en) | 2011-09-06 | 2023-12-19 | Allergan, Inc. | Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation |
| US11833269B2 (en) | 2011-09-06 | 2023-12-05 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
| US9821086B2 (en) | 2011-09-06 | 2017-11-21 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
| JP2016069286A (en) * | 2014-09-26 | 2016-05-09 | 株式会社ファンケル | L-ascorbic acid sustained-release formulation |
| US10722444B2 (en) | 2014-09-30 | 2020-07-28 | Allergan Industrie, Sas | Stable hydrogel compositions including additives |
| US11260015B2 (en) | 2015-02-09 | 2022-03-01 | Allergan Industrie, Sas | Compositions and methods for improving skin appearance |
| US12011500B2 (en) | 2015-02-09 | 2024-06-18 | Allergan Industrie, Sas | Compositions and methods for improving skin appearance |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4982718B2 (en) | 2012-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4982718B2 (en) | Composition for oral intake for beautiful skin | |
| KR101342192B1 (en) | Agent for enhancing collagen production and utilization of the same | |
| EP2255818B1 (en) | Oral or enteral composition useful for recovery of physical functions | |
| JP4249853B2 (en) | Oral skin moisturizer | |
| EP2609812B1 (en) | Liquid nucleotides/nucleosides-containing product | |
| JP4466972B2 (en) | Orally disintegrating N-acetylglucosamine tablets | |
| JP5635226B2 (en) | Hair papilla cell growth promoter | |
| JP4702745B2 (en) | Mineral absorption promoter and its use | |
| WO2005034938A1 (en) | Collagen productin enhancer and production process and use thereof | |
| JP2010064992A (en) | Peroxisome proliferator-activated receptor alpha-activating agent | |
| JP2010053122A (en) | Lipid synthesis inhibitor | |
| JP2005211078A (en) | Beauty and health food | |
| JP3575762B2 (en) | Nutritional composition containing coenzyme Q10 | |
| JP2007099653A (en) | Arthrodynia ameliorator | |
| JP5866667B2 (en) | Composition comprising stabilized phosphatidylserine | |
| JP5123574B2 (en) | Hyaluronic acid production enhancer | |
| KR101174385B1 (en) | Moisturizing agent | |
| JP2008024623A (en) | Oral composition | |
| KR102245628B1 (en) | Composition for internal use | |
| JP2009291130A (en) | Food composition | |
| JP2005206531A (en) | Agent for preventing skin aging | |
| JP3193019U (en) | Glucosamine-containing sugar-coated tablets | |
| JP2021045110A (en) | Composition for improving skin quality | |
| JP6382667B2 (en) | L-ascorbic acid sustained release preparation | |
| JPH11124390A (en) | Composition for treating dermatosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080801 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110920 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111118 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120313 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120327 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20120327 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4982718 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150511 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |